Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Michelle Hathaway

Physician Assistant, Medical Linwood, NJ Physician Assistant

NPI 1558798702 CMS profile 11076548

222 New Rd, Ste 201, Linwood, NJ 08221

Open in the dashboard

General payments

$6,178

392 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michelle Hathaway of Linwood, NJ is reported in the CMS Open Payments database as having received $6,178 across 392 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,175 71
2024 General $1,484 93
2023 General $1,540 91
2022 General $880 64
2021 General $1,099 73

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michelle Hathaway
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Michelle Hathaway were reported at $1,175. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Michelle Hathaway Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,099 $156 $41–$563 $132
2022 $880 $185 $55–$649 $149
2023 $1,540 $199 $58–$717 $160
2024 $1,484 $206 $62–$740 $164
2025 $1,175 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $1,923 127 payments
  2. Regeneron Healthcare Solutions, Inc. $835 39 payments
  3. AstraZeneca Pharmaceuticals LP $677 42 payments
  4. Mylan Specialty L.P. $518 45 payments
  5. Genzyme Corporation $450 30 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $341 24 payments
  7. Philips Electronics North America Corporation $305 19 payments
  8. Grifols USA, LLC $220 14 payments
  9. Amgen Inc. $187 12 payments
  10. Genentech USA, Inc. $182 11 payments
  11. Other $539 29 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,019 390 payments
  2. Education $159 2 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $1,105 81 payments
  2. DUPIXENT Inflammation And Immunology $621 30 payments
  3. NUCALA $570 44 payments
  4. YUPELRI $560 48 payments
  5. DUPIXENT Immunology $529 31 payments
  6. AREXVY $356 26 payments
  7. BREZTRI $287 16 payments
  8. SPIRIVA RESPIMAT $281 21 payments
  9. TEZSPIRE $237 12 payments
  10. Prolastin-C Liquid $220 14 payments
  11. Other $2,118 131 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,026

Median for Physician Assistant: 241

Drug cost

$338,919

Median for Physician Assistant: $4,110

Branded share of claims

58.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 200 $168,575
Nucala Mepolizumab Brand 14 $51,685
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 45 $34,141
Spiriva Respimat Tiotropium Bromide Brand 38 $26,920
Breo Ellipta Fluticasone/Vilanterol Brand 50 $24,248
Dulera Mometasone/Formoterol Brand 14 $6,667
Albuterol Sulfate Hfa Albuterol Sulfate Brand 163 $5,927
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 37 $5,439
Incruse Ellipta Umeclidinium Bromide Brand 15 $5,354
Wixela Inhub Fluticasone Propion/Salmeterol Brand 24 $2,386

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$149,526

Medicare's payments for the services billed

Medicare patients

537

Average age 75

Services billed

1,990

323 women, 214 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 59%
Diabetes 57%
Arthritis 57%
Depression 55%
Heart failure 48%
Ischemic heart disease 45%
Atrial fibrillation 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $368
  • GENZYME CORPORATION $142
$509 — —
YUPELRI
  • Mylan Specialty L.P. $180
$180 — —
NUCALA
  • GlaxoSmithKline, LLC. $128
$128 14 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $121
$121 200 —
AREXVY
  • GlaxoSmithKline, LLC. $121
$121 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

392 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record